Activated leukocyte cell adhesion molecule expression predicts lymph node metastasis in oral squamous cell carcinoma

Oral Oncology

Volumn 46, Issue 5, 2010, Pages 393-398

  van den Brand, Michiel ^a   Takes, Robert P ^a   Blokpoel deRuyter, Marianne ^a   Slootweg, Piet J ^a   van Kempen, Léon C L ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Activated leukocyte cell adhesion molecule; Lymphatic metastasis; Molecular markers; Oral cancer; Overall survival

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MOUTH CARCINOMA; NECK CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MOUTH NEOPLASMS; NEOPLASM PROTEINS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 77950867163     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2010.03.001     Document Type: Article

References (33)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
2. Blot W.J., McLaughlin J.K., Winn D.M., Austin D.F., Greenberg R.S., Preston-Martin S., et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 48 11 (1988) 3282-3287
3. Tuyns A.J., Esteve J., Raymond L., Berrino F., Benhamou E., Blanchet F., et al. Cancer of the larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France). Int J Cancer 41 4 (1988) 483-491
4. Gillison M.L., and Lowy D.R. A causal role for human papillomavirus in head and neck cancer. Lancet 363 9420 (2004) 1488-1489
5. Ferlito A., Shaha A.R., and Rinaldo A. The incidence of lymph node micrometastases in patients pathologically staged N0 in cancer of oral cavity and oropharynx. Oral Oncol 38 1 (2002) 3-5
6. Takes R.P. Staging of the neck in patients with head and neck squamous cell cancer: imaging techniques and biomarkers. Oral Oncol 40 7 (2004) 656-667
7. Liu M., Lawson G., Delos M., Jamart J., Chatelain B., Remacle M., et al. Prognostic value of cell proliferation markers, tumour suppressor proteins and cell adhesion molecules in primary squamous cell carcinoma of the larynx and hypopharynx. Eur Arch Otorhinolaryngol 260 1 (2003) 28-34
8. Takes R.P., Baatenburg de Jong R.J., Schuuring E., Hermans J., Vis A.A., Litvinov S.V., et al. Markers for assessment of nodal metastasis in laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 123 4 (1997) 412-419
9. Schipper J.H., Unger A., and Jahnke K. E-cadherin as a functional marker of the differentiation and invasiveness of squamous cell carcinoma of the head and neck. Clin Otolaryngol Allied Sci 19 5 (1994) 381-384
10. Schipper J.H., Frixen U.H., Behrens J., Unger A., Jahnke K., and Birchmeier W. E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res 51 23Pt 1 (1991) 6328-6337
11. Bowie G.L., Caslin A.W., Roland N.J., Field J.K., Jones A.S., and Kinsella A.R. Expression of the cell-cell adhesion molecule E-cadherin in squamous cell carcinoma of the head and neck. Clin Otolaryngol Allied Sci 18 3 (1993) 196-201
12. Mattijssen V., Peters H.M., Schalkwijk L., Manni J.J., van '.-G., de Mulder P.H., et al. E-cadherin expression in head and neck squamous-cell carcinoma is associated with clinical outcome. Int J Cancer 5 4 (1993) 580-585
13. Andrews N.A., Jones A.S., Helliwell T.R., and Kinsella A.R. Expression of the E-cadherin-catenin cell adhesion complex in primary squamous cell carcinomas of the head and neck and their nodal metastases. Br J Cancer 75 10 (1997) 1474-1480
14. Masuda M., Kuratomi Y., Shiratsuchi H., Nakashima T., Naonobu K., and Komiyama S. Decreased CD44H expression in early-stage tongue carcinoma associates with late nodal metastases following interstitial brachytherapy. Head Neck 22 7 (2000) 662-665
15. van Kempen L.C., van den Oord J.J., van Muijen G.N., Weidle U.H., Bloemers H.P., and Swart G.W. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 156 3 (2000) 769-774
16. Verma A., Shukla N.K., Deo S.V., Gupta S.D., and Ralhan R. MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology 68 4-6 (2005) 462-470
17. Weichert W., Knosel T., Bellach J., Dietel M., and Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 57 11 (2004) 1160-1164
18. Mezzanzanica D., Fabbi M., Bagnoli M., Staurengo S., Losa M., Balladore E., et al. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 14 6 (2008) 1726-1733
19. Burkhardt M., Mayordomo E., Winzer K.J., Fritzsche F., Gansukh T., Pahl S., et al. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol 59 4 (2006) 403-409
20. Kristiansen G., Pilarsky C., Wissmann C., Stephan C., Weissbach L., Loy V., et al. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 54 1 (2003) 34-43
21. Sawhney M., Matta A., Macha M.A., Kaur J., DattaGupta S., Shukla N.K., et al. Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients. Int J Cancer 124 9 (2009) 2098-2105
22. Sawhney M., Matta A., Macha M.A., Kaur J., DattaGupta S., Shukla N.K., et al. Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients. Int J Cancer 124 9 (2009) 2098-2105
23. van Kempen L.C., van den Oord J.J., van Muijen G.N., Weidle U.H., Bloemers H.P., and Swart G.W. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 156 3 (2000) 769-774
24. Mezzanzanica D., Fabbi M., Bagnoli M., Staurengo S., Losa M., Balladore E., et al. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 14 6 (2008) 1726-1733
25. Weichert W., Knosel T., Bellach J., Dietel M., and Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 57 11 (2004) 1160-1164
26. Kristiansen G., Pilarsky C., Wissmann C., Stephan C., Weissbach L., Loy V., et al. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 54 1 (2003) 34-43
27. van Kempen L.C., van den Oord J.J., van Muijen G.N., Weidle U.H., Bloemers H.P., and Swart G.W. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 156 3 (2000) 769-774
28. Kristiansen G., Pilarsky C., Wissmann C., Stephan C., Weissbach L., Loy V., et al. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 54 1 (2003) 34-43
29. van Kempen L.C., Meier F., Egeblad M., Kersten-Niessen M.J., Garbe C., Weidle U.H., et al. Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. J Invest Dermatol 122 5 (2004) 1293-1301
30. Swart G.W., Lunter P.C., Kilsdonk J.W., and Kempen L.C. Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration?. Cancer Metastasis Rev 24 2 (2005) 223-236
31. Lunter P.C., van Kilsdonk J.W., van Kilsdonk J.W., van B.H., Cornelissen I.M., Bergers M., Willems P.H., et al. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res 65 19 (2005) 8801-8808
32. Sawhney M., Matta A., Macha M.A., Kaur J., DattaGupta S., Shukla N.K., et al. Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients. Int J Cancer 124 9 (2009) 2098-2105
33. Roepman P., Wessels L.F., Kettelarij N., Kemmeren P., Miles A.J., Lijnzaad P., et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 37 2 (2005) 182-186